Lasa Supergenerics appoints Janardan Savala as additional executive director
- Janardan Kamlu Savala appointed as additional executive director on August 26, 2026
- Term spans five years until August 25, 2031
- Appointment requires shareholder approval via general meeting or postal ballot
- Savala brings expertise in banking coordination and compliance processes
*this image is generated using AI for illustrative purposes only.
Lasa Supergenerics appointed Janardan Kamlu Savala as an additional executive director on August 26, 2026. The board approved the appointment during its meeting held that day. Shareholder approval is required for the position to become permanent.
The company disclosed the outcome pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 11:00 am and concluded at 1:00 pm.
Appointment Details
Savala will serve as an occupier of all units of the company. His term runs from August 26, 2026, to August 25, 2031. The appointment remains subject to ratification by members at the ensuing general meeting or via postal ballot.
| Detail | Information |
|---|---|
| Name | Janardan Kamlu Savala |
| Role | Additional Director (Executive) |
| Term Start | August 26, 2026 |
| Term End | August 25, 2031 |
| DIN | 11913583 |
Profile and Expertise
Savala, born on May 15, 1994, holds an undergraduate degree. He brings experience in business operations and commercial practices. His expertise includes coordination with financial institutions and handling banking formalities. He facilitates documentation and compliance-related interactions.
He currently holds no directorships in other public companies. He also holds no memberships or chairmanships in audit or stakeholders' relationships committees across public companies. Savala does not hold any shares in Lasa Supergenerics.
Historical Stock Returns for Lasa Supergenerics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.45% | -1.48% | -16.65% | -15.59% | -37.46% | -91.00% |
How might Janardan Savala's expertise in banking formalities and financial coordination influence Lasa Supergenerics' future capital raising or debt management strategies?
What strategic operational changes or commercial expansions are anticipated under Savala's leadership during his five-year term ending in 2031?
Could the appointment of a relatively young executive director signal a shift in the company's corporate governance culture or succession planning?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
